PathoQuest announces the appointment of Audrey Brussel, Ph.D. to the newly created position of Viral Safety Leader. Her addition to the company will strengthen PathoQuest’s in-house expertise in viral safety. Her insights and knowledge of the pharmaceutical industry from a customer’s perspective will help deliver a better service and support the growth of the company’s rapidly expanding quality control testing business for biologics.
PathoQuest receives PM’up Relance Industrie Île-de-France grant to expand biologic testing capabilities at Paris site
PathoQuest, has received support from the Île-de-France region (France) as part of the PM’up Relance Industrie program to accelerate the industrialization of the company’s high value-added service for quality control testing of biologics and to help sustain its fast-paced growth both in France and internationally.
PathoQuest has established a U.S. subsidiary, PathoQuest, Inc., and will construct a state-of-the-art next-generation sequencing (NGS)-based testing laboratory at Charles River’s site in Wayne, PA.
PathoQuest laboratory activities will not be disturbed, some of our support activities will be performed remotely when possible but our offices and labs remain open and our team is ready to work with you on new projects.
PathoQuest obtains Pharmaceutical Establishment status from French ANSM for its biological drug testing activities
PathoQuest announced that it has obtained the administrative authorization of Pharmaceutical Establishment from the French Agence Nationale de Sécurité du Médicament (ANSM) for its biological drug testing activities.
PathoQuest’s Paris Based Facility Obtains GLP Conformity Certificate for its Biologics Genomic Testing Services Based on Next-Generation Sequencing Technology
PathoQuest, announced that it has received GLP certificate of conformity following a successful inspection by the French National Agency for Medicine and Health Products Safety (ANSM). PathoQuest is the first company in France to receive such a certificate from the ANSM for NGS viral safety testing. (“high-throughput sequencing detection of incidental replicative virus test in eukaryote cells”).